Tesamorelin and CJC-1295 are often compared as two flavors of the same thing — and mechanically, they are. Both are GHRH analogs: lab-made copies of growth-hormone-releasing hormone that prompt the body's own growth hormone. But the comparison that actually matters isn't mechanism. It's that one of them is an approved medicine and the other is a research compound.
In plain terms: same engine, very different amounts of proof under the hood.
Same lever, different engineering
Both activate the GHRH receptor — the "release growth hormone" lever (the other lever, ghrelin, belongs to ipamorelin). Where they differ is how each is built to resist being broken down:
| Tesamorelin | CJC-1295 | |
|---|---|---|
| Class | GHRH analog | GHRH analog |
| Built from | Stabilised GHRH(1-44) | Substituted GHRH(1-29); DAC form adds albumin binding |
| Half-life | Short-to-moderate | Long (DAC) / minutes (no-DAC) |
| Status | FDA-approved (Egrifta) | Research compound |
| Human efficacy data | Placebo-controlled trials | None (pharmacokinetic data only) |
CJC-1295's long-acting behavior comes from the DAC modification that anchors it to albumin; tesamorelin is stabilised a different way but isn't engineered for the same multi-day persistence.
What the studies actually found
This table is where the two really separate:
| Study | Model | Key result | Year |
|---|---|---|---|
| Teichman et al.3 | Human (CJC-1295 DAC) | Raised growth hormone 6+ days and IGF-1 9–11 days — but measured hormone *levels*, not a health outcome | 2006 |
| Falutz et al. (NEJM)1 | Human RCT (tesamorelin, HIV lipodystrophy) | Cut visceral fat ~15% vs placebo over 26 weeks — a real clinical *outcome* | 2007 |
| FDA approval (Egrifta)2 | US regulatory | Tesamorelin approved to reduce HIV-associated visceral fat | 2010 |
In plain terms: CJC-1295 has been shown to move the right hormones in people; tesamorelin has been shown to produce an actual result (less belly fat) in a placebo-controlled trial, and cleared the FDA bar for it. That's the difference between promising pharmacology and proven benefit.
Two axes, not one
- Within the class, the practical difference is duration — same lever, different level-curve shapes, as with most GHRH comparisons.
- Across the class, the honest difference is evidence — an approved drug with outcome trials versus a research peptide with only pharmacokinetic data.
The mechanism table makes them look like twins; the evidence table shows they're not.
The honest bottom line
If someone treats tesamorelin and CJC-1295 as interchangeable, they're right about the mechanism and wrong about the standing. Tesamorelin has a narrow but real approval and placebo-controlled proof; CJC-1295 remains a research compound whose human data is about hormone levels, not proven results. Deeper detail in what is tesamorelin, what is CJC-1295, and growth-hormone secretagogues explained. Educational overview only, not medical advice.